Truist Securities Reiterates Buy on Genmab, Maintains $54 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Asthika Goonewardene has reiterated a 'Buy' rating on Genmab (NASDAQ:GMAB) and maintained a price target of $54.
September 26, 2023 | 4:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated a 'Buy' rating on Genmab and maintained a price target of $54.
The reiteration of a 'Buy' rating by Truist Securities indicates a positive outlook for Genmab. The maintained price target of $54 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100